Compare Becton Dickinson and Co (BDX) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Recursion Pharmaceuticals Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $49.41B), while Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.81B). The key difference: Becton Dickinson and Co is far larger — about 27.3× Recursion Pharmaceuticals Inc's market cap, and Becton Dickinson and Co pays a 2.32% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| BDX | RXRX | |
|---|---|---|
Market Cap | $49.41B | $1.81B |
Sector | Health | Health |
52-Week High | $185.39 | $6.79 |
52-Week Low | $138.62 | $2.84 |
Enterprise Value | $65.51B | $1.33B |
Dividend Yield | 2.32% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
